Victoria L. Brown's most recent trade in Apellis Pharmaceuticals Inc was a trade of 1,412 Common Stock done at an average price of $52.1 . Disclosure was reported to the exchange on Jan. 20, 2023.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Apellis Pharmaceuticals Inc | Victoria L. Brown | Program Team Lead | Payment of exercise price or tax liability using portion of securities received from the company at price $ 52.05 per share. | 20 Jan 2023 | 1,412 | 23,556 (0%) | 0% | 52.1 | 73,495 | Common Stock |
| Apellis Pharmaceuticals Inc | Victoria L. Brown | Program Team Lead | Payment of exercise price or tax liability using portion of securities received from the company at price $ 58.41 per share. | 26 Oct 2022 | 130 | 24,844 (0%) | 0% | 58.4 | 7,593 | Common Stock |
| Apellis Pharmaceuticals Inc | Victoria L. Brown | Program Team Lead | Sale of securities on an exchange or to another person at price $ 45.00 per share. | 17 Jun 2022 | 2,698 | 24,974 (0%) | 0% | 45 | 121,410 | Common Stock |
| Apellis Pharmaceuticals Inc | Victoria L. Brown | Program Team Lead | Payment of exercise price or tax liability using portion of securities received from the company at price $ 49.28 per share. | 25 Mar 2022 | 82 | 28,325 (0%) | 0% | 49.3 | 4,041 | Common Stock |
| Apellis Pharmaceuticals Inc | Victoria L. Brown | Program Team Lead | Payment of exercise price or tax liability using portion of securities received from the company at price $ 47.12 per share. | 10 Feb 2022 | 175 | 28,407 (0%) | 0% | 47.1 | 8,246 | Common Stock |
| Apellis Pharmaceuticals Inc | Victoria L. Brown | Program Team Lead | Payment of exercise price or tax liability using portion of securities received from the company at price $ 38.59 per share. | 28 Jan 2022 | 434 | 28,582 (0%) | 0% | 38.6 | 16,748 | Common Stock |
| Apellis Pharmaceuticals Inc | Victoria L. Brown | Program Team Lead | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jan 2022 | 24,774 | 24,774 | - | - | Stock Option (Right to Buy) | |
| Apellis Pharmaceuticals Inc | Victoria L. Brown | Program Team Lead | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jan 2022 | 17,466 | 29,016 (0%) | 0% | 0 | Common Stock | |
| Apellis Pharmaceuticals Inc | Victoria L. Brown | Program Team Lead | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Oct 2021 | 882 | 11,422 (0%) | 0% | 0 | Common Stock | |
| Apellis Pharmaceuticals Inc | Victoria L. Brown | Program Team Lead | Payment of exercise price or tax liability using portion of securities received from the company at price $ 41.16 per share. | 25 Mar 2021 | 82 | 9,952 (0%) | 0% | 41.2 | 3,375 | Common Stock |
| Apellis Pharmaceuticals Inc | Victoria L. Brown | Program Team Lead | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2021 | 7,500 | 7,500 | - | - | Stock Option (Right to Buy) | |
| Apellis Pharmaceuticals Inc | Victoria L. Brown | Program Team Lead | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2021 | 1,250 | 10,034 (0%) | 0% | 0 | Common Stock | |
| Apellis Pharmaceuticals Inc | Victoria L. Brown | Program Team Lead | Payment of exercise price or tax liability using portion of securities received from the company at price $ 47.72 per share. | 10 Feb 2021 | 144 | 8,784 (0%) | 0% | 47.7 | 6,872 | Common Stock |
| Apellis Pharmaceuticals Inc | Victoria L. Brown | Program Team Lead | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Jan 2021 | 30,000 | 30,000 | - | - | Stock Option (Right to Buy) | |
| Apellis Pharmaceuticals Inc | Victoria L. Brown | Program Team Lead | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Jan 2021 | 5,000 | 8,928 (0%) | 0% | 0 | Common Stock | |
| Apellis Pharmaceuticals Inc | Victoria L. Brown | Program Team Lead | Sale of securities on an exchange or to another person at price $ 35.00 per share. | 07 Oct 2020 | 12,000 | 3,607 (0%) | 0% | 35 | 420,000 | Common Stock |
| Apellis Pharmaceuticals Inc | Victoria L. Brown | Program Team Lead | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Oct 2020 | 12,000 | 39,268 | - | - | Stock Option (Right to Buy) | |
| Apellis Pharmaceuticals Inc | Victoria L. Brown | Program Team Lead | Exercise or conversion of derivative security received from the company (such as an option) at price $ 18.98 per share. | 07 Oct 2020 | 12,000 | 15,607 (0%) | 0% | 19.0 | 227,760 | Common Stock |